Global Neurology Academy
The Global Neurology Academy (GNA) series offers certified education modules and video interviews from leading MS experts from across the globe as they address topics such as induction therapy in relapsing-remitting multiple sclerosis; No Evidence of Disease Activity (NEDA) concept; how different agents used in MS management may be utilized in induction therapy; appreciation of how reductions in end-organ damage impact patient quality-of-life; mechanisms of action of the classical as well as emergent agents; key issues associated with making the correct differential diagnosis of multiple sclerosis, in addition to how best to incorporate prognostic indicators into clinical decision-making; current and emergent novel oral agents in MS management; and diagnostic strategies and identifying predictors of outcome.
For more information about GNA, visit www.globalneurologyacademy.org.
1-15 of 221
When “Mild” Matters Most: Closing Clinical Gaps in Early Symptomatic AD
CME/CE Virtual EventWhen “Mild” Matters Most: Closing Clinical Gaps in Early Symptomatic AD
June 03, 2026
06:00 PM - 07:00 PM CEST
FXIa Remix! Keeping the Flow Without Missing a Beat
CME/CEFXIa Remix! Keeping the Flow Without Missing a Beat
Mike Sharma, MD, MSc, FRCPC
Ashkan Shoamanesh, MD
Brian Mac Grory, MB, BCh BAO, MRCP, FAHA, FANA
Understanding Variability in Myasthenia Gravis
NeuroFrontiersUnderstanding Variability in Myasthenia Gravis
Henry Kaminski, MD
Examining the Global Genetic Prevalence of TK2d
NeuroFrontiersExamining the Global Genetic Prevalence of TK2d
Brian P. McDonough, MD, FAAFP
Austin Larson, MD
Microglia Drive Neurodegeneration in Friedreich’s Ataxia
NeuroFrontiersMicroglia Drive Neurodegeneration in Friedreich’s Ataxia
Ryan Quigley
Is Friedreich’s Ataxia Developmental or Degenerative?
NeuroFrontiersIs Friedreich’s Ataxia Developmental or Degenerative?
Arnulf Koeppen, MD
- advertisement
Unpacking the Genetics of Friedreich’s Ataxia
NeuroFrontiersUnpacking the Genetics of Friedreich’s Ataxia
Arnulf Koeppen, MD
Friedreich’s Ataxia: Impact of Frataxin Loss
NeuroFrontiersFriedreich’s Ataxia: Impact of Frataxin Loss
Arnulf Koeppen, MD
BCMA mRNA CAR-T Shows Durable Benefit in MG
NeuroFrontiersBCMA mRNA CAR-T Shows Durable Benefit in MG
FA hiPSCs in Translational Drug Development
NeuroFrontiersFA hiPSCs in Translational Drug Development
Omaveloxolone in Friedreich’s Ataxia: Early Real-World Signals
NeuroFrontiersOmaveloxolone in Friedreich’s Ataxia: Early Real-World Signals
Advancing Pediatric MS Care: Insights from AAN 2026
NeuroFrontiersAdvancing Pediatric MS Care: Insights from AAN 2026
Elizabeth Wilson, MD
- advertisement
Emerging Serum microRNAs as Early Signals in MS
NeuroFrontiersEmerging Serum microRNAs as Early Signals in MS
Strengthening Global Infrastructure for FSHD Trials
AudioAbstractsStrengthening Global Infrastructure for FSHD Trials
Marlene Mimi Maeusli, PhD.
Spinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
NeuroFrontiersSpinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
